+65 3158 9910
1300 798 820
+64 9801 0299
When the ExteNET study was undertaken, researchers did not provide prophylactic anti-diarrhoeal medications to those patients enrolled, despite neratinib being a TKI absorbed through the bowel.
The CONTROL trial is an open label Phase 2 study investigating whether the incidence and severity of diarrhoea can be reduced in patients with early-stage HER2+ breast via prophylactic management.
Professor Arlene Chan has enrolled more than 50 patients in this study and in this piece, discusses the trial and her anecdotal findings prior to full publication.